Condition
Acute Gout Flare
Total Trials
5
Recruiting
3
Active
3
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (2)
P 2 (2)
P 3 (1)
Trial Status
Recruiting3
Completed2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05658575Phase 2RecruitingPrimary
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT07295496Phase 1RecruitingPrimary
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
NCT07145229Phase 2Recruiting
Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare
NCT06258213Phase 1Completed
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ABP-745 Administration in Healthy Volunteers
NCT00855920Phase 3CompletedPrimary
Study Utilizing Rilonacept in Gout Exacerbations
Showing all 5 trials